Bayforest Capital’s Blueprint Medicines BPMC Stock Holding History

Bayforest Capital’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1,112	Closed	-$143K	–	745
2025 Q2	$143K	Buy	1,112 +1,099	+8,454%	+$114K	0.06%	432
2025 Q1	$1.15K	Sell	13 -2,872	-100%	-$280K	﹤0.01%	707
2024 Q4	$252K	Buy	+2,885	New	+$264K	0.32%	74

Other funds holding BPMC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Bayforest Capital's BPMC Position: Q3 2025 in Review

Bayforest Capital sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 1,112 shares — an estimated $143K sold.

Bayforest Capital first reported a position in BPMC in Q4 2024 and held it in 3 quarters. The position peaked at $252K in Q4 2024. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

Bayforest Capital reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
Bayforest Capital sold 1,112 Blueprint Medicines shares in Q3 2025, an estimated $143K.
Bayforest Capital first reported a position in Blueprint Medicines in Q4 2024 and held it in 3 quarters.
Bayforest Capital's Blueprint Medicines position peaked at $252K in Q4 2024.
5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Bayforest Capital's 13F filing for Q3 2025, filed 24 Oct 2025.